Nothing Special   »   [go: up one dir, main page]

PA8842101A1 - Heteroarilos sustituidos - Google Patents

Heteroarilos sustituidos

Info

Publication number
PA8842101A1
PA8842101A1 PA20098842101A PA8842101A PA8842101A1 PA 8842101 A1 PA8842101 A1 PA 8842101A1 PA 20098842101 A PA20098842101 A PA 20098842101A PA 8842101 A PA8842101 A PA 8842101A PA 8842101 A1 PA8842101 A1 PA 8842101A1
Authority
PA
Panama
Prior art keywords
heteroarilos
substituted
glucoquinase
affections
activators
Prior art date
Application number
PA20098842101A
Other languages
English (en)
Inventor
William Benbow John
Lou Jihong
Allen Pfefferkorn Jeffrey
Mike Tu Meihua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8842101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PA8842101A1 publication Critical patent/PA8842101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DE FÓRMULA (1A) QUE ACTÚAN COMO ACTIVADORES DE GLUCOQUINASA; COMPOSICIONES FARMACÉUTICAS DE LOS MISMOS, Y MÉTODOS PARA TRATAR ENFERMEDADES, TRASTORNOS O AFECCIONES MEDIADAS POR GLUCOQUINASA X, Y, Z, R1 , R2 , R3 Y R4 SON COMO SE HAN DESCRITO EN LA PRESENTE MEMORIA.
PA20098842101A 2008-09-11 2009-09-10 Heteroarilos sustituidos PA8842101A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9605608P 2008-09-11 2008-09-11
US23257809P 2009-08-10 2009-08-10

Publications (1)

Publication Number Publication Date
PA8842101A1 true PA8842101A1 (es) 2010-04-21

Family

ID=41228587

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098842101A PA8842101A1 (es) 2008-09-11 2009-09-10 Heteroarilos sustituidos

Country Status (29)

Country Link
US (4) US7977367B2 (es)
EP (1) EP2344458A1 (es)
JP (2) JP4907746B2 (es)
KR (1) KR101258331B1 (es)
CN (1) CN102216276A (es)
AP (1) AP2011005613A0 (es)
AR (1) AR073283A1 (es)
AU (1) AU2009290474A1 (es)
BR (1) BRPI0918128A2 (es)
CA (1) CA2735184C (es)
CL (1) CL2011000478A1 (es)
CO (1) CO6361937A2 (es)
CR (1) CR20110103A (es)
DO (1) DOP2011000076A (es)
EA (1) EA201100311A1 (es)
EC (1) ECSP11010885A (es)
GE (1) GEP20135793B (es)
IL (1) IL211411A0 (es)
MA (1) MA32627B1 (es)
MX (1) MX2011002613A (es)
NI (1) NI201100050A (es)
NZ (1) NZ591366A (es)
PA (1) PA8842101A1 (es)
PE (1) PE20110303A1 (es)
SV (1) SV2011003855A (es)
TW (1) TWI382026B (es)
UY (1) UY32098A (es)
WO (1) WO2010029461A1 (es)
ZA (1) ZA201101364B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2454229B1 (en) * 2009-05-06 2017-09-13 Risen (Shanghai) Pharma Tech Co, Ltd. Amino acid derivatives for the treatment of neuropathic pain
ES2893699T3 (es) 2010-03-31 2022-02-09 Scripps Research Inst Reprogramación de células
MX2013004193A (es) * 2010-11-11 2013-06-05 Sanofi Sa Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
WO2013113782A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113781A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds i
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US9072301B2 (en) 2012-02-03 2015-07-07 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113719A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds ii
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
CA2862354A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US9462809B2 (en) 2012-03-13 2016-10-11 Basf Se Fungicidal pyrimidine compounds
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
PT2871180T (pt) 2012-07-04 2018-05-08 Agro Kanesho Co Ltd Derivado de éster do ácido 2-aminonicotínico e bactericida que o contém como ingrediente ativo
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
US10472376B2 (en) 2013-07-03 2019-11-12 Takeda Pharmaceutical Company Limited Amide compound
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
AR099677A1 (es) 2014-03-07 2016-08-10 Sumitomo Chemical Co Compuesto heterocíclico fusionado y su uso para el control de plagas
US10604541B2 (en) 2016-07-22 2020-03-31 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
TW201840578A (zh) * 2017-02-22 2018-11-16 以色列商亞當阿甘公司 製備甲基膦酸丁基酯的方法
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN109134535B (zh) * 2018-10-22 2021-03-19 江苏长青农化股份有限公司 一种甲基磷酸酯的制备方法
CN116018337A (zh) * 2020-08-25 2023-04-25 亥姆霍兹感染研究中心有限公司 铜绿假单胞菌毒力因子LasB抑制剂
KR20240032841A (ko) 2021-07-08 2024-03-12 이시하라 산교 가부시끼가이샤 살선충 조성물

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
US5399564A (en) 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
WO1994001415A1 (en) 1992-07-03 1994-01-20 Kumiai Chemical Industry Co., Ltd. Condensed heterocyclic derivative and weedkiller
KR100381584B1 (ko) 1994-07-22 2003-08-21 알타나 파마 아게 디히드로벤조푸란
DE4434637A1 (de) 1994-09-28 1996-04-04 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
WO1996011920A1 (en) 1994-10-13 1996-04-25 Pfizer Inc. Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4 (ltb4) antagonists
WO1996011925A1 (en) 1994-10-13 1996-04-25 Pfizer Inc. Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4' (ltb4) antagonists
DE19603576A1 (de) 1996-02-01 1997-08-07 Bayer Ag Acylierte 4-Amino und 4-Hydrazinopyrimidine
EP0901482B1 (en) 1996-05-20 2003-05-02 Darwin Discovery Limited Benzofuran carboxamides and their therapeutic use
JP4309475B2 (ja) 1996-08-19 2009-08-05 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンゾフラン―４―カルボキサミド
EP1054884A1 (en) 1998-02-09 2000-11-29 Darwin Discovery Limited Benzofuran-4-carboxamides and their therapeutic use
CA2359113A1 (en) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
US6670380B2 (en) 2000-11-20 2003-12-30 Bristol-Myers Squibb Co. Pyridone inhibitors of fatty acid binding protein and method
AU2002221902B2 (en) * 2000-12-06 2006-11-23 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CA2464214C (en) 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
KR100705519B1 (ko) 2002-02-14 2007-04-10 파마시아 코포레이션 Ｐ３８ ｍａｐ 키나제의 조절제로서의 치환된 피리디논
CN100357283C (zh) 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
JP2005538047A (ja) 2002-05-03 2005-12-15 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ボンベシンアンタゴニスト
JP4287816B2 (ja) 2002-06-13 2009-07-01 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー ピラゾールカルボキサミド殺虫剤
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1433778A1 (en) 2002-12-23 2004-06-30 Jerini AG Use of nitriles as rotamase inhibitors
EP1594863A1 (en) * 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
JP4400563B2 (ja) 2003-02-13 2010-01-20 萬有製薬株式会社 新規２−ピリジンカルボキサミド誘導体
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
WO2004076420A1 (ja) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
WO2005009993A1 (en) 2003-07-15 2005-02-03 Smithkline Beecham Corporation Novel compounds
JP4727578B2 (ja) 2003-08-01 2011-07-20 中外製薬株式会社 マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用な複素環式化合物
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
US7750020B2 (en) * 2004-04-02 2010-07-06 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of Type 2 diabetes
JP4719745B2 (ja) 2004-07-29 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャンネル阻害剤
US20060058525A1 (en) 2004-09-01 2006-03-16 Rajinder Singh Synthesis of 2,4-pyrimidinediamine compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
BRPI0516381A (pt) 2004-12-21 2008-09-02 Hoffmann La Roche derivados de cromano e seu uso como ligandos de receptor de 5-ht
JP4167218B2 (ja) 2004-12-22 2008-10-15 株式会社メタル建材 薄板用タッピンねじ
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JP2008534664A (ja) 2005-04-06 2008-08-28 アストラゼネカ アクチボラグ 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
RU2008112184A (ru) 2005-08-31 2009-10-10 Астеллас Фарма Инк. (Jp) Производное тиазола
JP2009013065A (ja) 2005-10-14 2009-01-22 Astellas Pharma Inc 縮合へテロ環化合物
EP1951680A4 (en) 2005-11-15 2011-08-10 Astrazeneca Ab NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
EP1999135A2 (en) 2006-03-30 2008-12-10 Takeda San Diego, Inc. Kinase inhibitors
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
JP2010138073A (ja) 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
JP2010529109A (ja) 2007-06-08 2010-08-26 アドビナス セラピュティックス プライベート リミテッド グルコキナーゼ活性化因子としてのピロール−２−カルボキサミド誘導体、そのプロセス及び薬学的応用
KR20110018366A (ko) * 2008-05-16 2011-02-23 다케다 샌디에고, 인코포레이티드 글루코키나아제 활성제
CA2748587A1 (en) 2009-01-20 2010-07-29 Pfizer Inc. Substituted pyrazinone amides

Also Published As

Publication number Publication date
EP2344458A1 (en) 2011-07-20
IL211411A0 (en) 2011-05-31
NI201100050A (es) 2011-09-27
NZ591366A (en) 2012-05-25
EA201100311A1 (ru) 2011-10-31
UY32098A (es) 2010-04-30
WO2010029461A1 (en) 2010-03-18
JP4907746B2 (ja) 2012-04-04
TW201010998A (en) 2010-03-16
GEP20135793B (en) 2013-03-25
US20110230445A1 (en) 2011-09-22
US20130165452A1 (en) 2013-06-27
AR073283A1 (es) 2010-10-28
PE20110303A1 (es) 2011-05-21
MX2011002613A (es) 2011-05-23
JP2012092115A (ja) 2012-05-17
TWI382026B (zh) 2013-01-11
US8389552B2 (en) 2013-03-05
ZA201101364B (en) 2012-04-25
CA2735184C (en) 2013-05-28
JP2012502091A (ja) 2012-01-26
CA2735184A1 (en) 2010-03-18
CL2011000478A1 (es) 2011-06-17
SV2011003855A (es) 2011-05-16
ECSP11010885A (es) 2011-04-29
AP2011005613A0 (en) 2011-04-30
DOP2011000076A (es) 2011-03-31
CN102216276A (zh) 2011-10-12
JP5225452B2 (ja) 2013-07-03
US20120225910A1 (en) 2012-09-06
BRPI0918128A2 (pt) 2015-11-24
US8329920B2 (en) 2012-12-11
CO6361937A2 (es) 2012-01-20
KR101258331B1 (ko) 2013-04-26
US20100063063A1 (en) 2010-03-11
US7977367B2 (en) 2011-07-12
AU2009290474A1 (en) 2010-03-18
KR20110043748A (ko) 2011-04-27
CR20110103A (es) 2011-03-14
MA32627B1 (fr) 2011-09-01

Similar Documents

Publication Publication Date Title
PA8842101A1 (es) Heteroarilos sustituidos
ECSP11011306A (es) Derivados de benzofuranilo
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
PA8855001A1 (es) Monocarbamas
UY29640A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado, y su uso como agentes farmacéuticos.
UY32385A (es) Amidas de pirazinona sustituida
SV2011003821A (es) Compuestos de fenantrenona, composiciones y metodos
UY32447A (es) Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
UY32154A (es) Derivados de isoquinolinona, procesos para su preparacion, composiciones farmaceuticas que los contiene y su uso en terapia
CU20110054A7 (es) Derivados heteroaril amida y sus usos como glucoquinasa activadores
CY1114207T1 (el) Παραγωγα βενζοφουρανυλιου για χρηση ως αναστολεις γλυκοκινασης
DOP2004000873A (es) Compuestos de benzopirano para uso en el tratamiento y la prevencion de afecciones relacionadas con la inflamacion